PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 6577-6581

  Wang, R C ^a   Jiang, D M ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin; Peroxisome proliferator activated receptor; Rats; Tumor necrosis factor

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; URATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; GOUT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIUM; AGONISTS; ANIMAL; ARTHRITIS, GOUTY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME; WISTAR RAT;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, GOUTY; CYTOKINES; GENE EXPRESSION REGULATION; INTERFERON-GAMMA; INTERLEUKIN-1BETA; MALE; PPAR GAMMA; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907146623     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.August.28.2     Document Type: Article

References (12)

1. Bongartz T, Coras B, Vogt T, Scholmerich J, et al. (2005). Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study. Rheumatology 44: 126-129.
2. Cuzzocrea S, Mazzon E, Dugo L, Patel NS, et al. (2003). Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor γ. Arthritis Rheum. 48: 3544-3556.
3. Fam AG (2002). Gout, diet, and the insulin resistance syndrome. J. Rheumatol. 29: 1350-1355.
4. Finnegan A, Mikecz K, Tao P and Glant TT (1999). Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1- type disease regulated by Th2 cytokines. J. Immunol. 163: 5383-5390.
5. Huang HG, Han XH, Han CG, Yuan GS, et al. (2005a). The role of pioglitazone, an agonist of the peroxisome proliferator-activated receptor γ, in the resolution of monosodium urate monohydrate crystal-induced inflammations. Chin. J. Rheumatol. 9: 463-468.
6. Huang HG, YF Sun and Hu M (2005b). Rats with acute gouty arthritis model and characteristics. Milit. Med. Sci. 29: 538-542.
7. Huang HG, Wang ZJ, Zhang YB, Shi HY, et al. (2007). Effects of pioglitazone on cytokine expressions in synovium in rats with acute gouty arthritis. Tianjin Med. J. 35: 124-126.
8. Kobayashi T, Notoya K, Naito T, Unno S, et al. (2005). Pioglitazone, a peroxisome proliferator-activated receptor γ agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum. 52: 479-487.
9. Kushnarenko NN and Govorin AV (2012). The alterations in fatty acids content of membranes of erythrocytes and insulin resistance syndrome under primary gout. Klin. Lab. Diagn. 17-19.
10. Oates JC, Reilly CM, Crosby MB and Gilkeson GS (2002). Peroxisome proliferator-activated receptor γ agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum. 46: 598-605.
11. Pascual E and Pedraz T (2004). Gout. Curr. Opin. Rheumatol. 16: 282-286.
12. Weinberger A and Pinkhas J (1980). A hypothesis on the possible role of interferon in the initiation of acute gouty arthritis attack. Med. Hypotheses 6: 781-784.